YEAR | COMPANY | POSITION | SALARY | INCREMENT |
---|---|---|---|---|
2023 | Immunome Inc | Independent Director | 55.7 K | 1.0 % |
2022 | NeuBase Therapeutics Inc | Independent Director | 68.3 K | -52.2 % |
2022 | Immunome Inc | Independent Director | 55.1 K | -50.1 % |
2022 | Lantern Pharma Inc | Independent Director | 51 K | 38.2 % |
2021 | NeuBase Therapeutics Inc | Independent Director | 142.9 K | 24.2 % |
2021 | Immunome Inc | Independent Director | 110.4 K | - |
2021 | Lantern Pharma Inc | Independent Director | 36.9 K | -65.1 % |
2020 | NeuBase Therapeutics Inc | Independent Director | 115.0 K | -86.4 % |
2020 | Lantern Pharma Inc | Independent Director | 105.6 K | - |
2019 | NeuBase Therapeutics Inc | Independent Director | 847.4 K | - |
2019 | Lantern Pharma Inc | Director | - | - |
2017 | Lilly(Eli) & Co | Independent Director | 116.3 K | -58.3 % |
2016 | Lilly(Eli) & Co | Independent Director | 279 K | 5.7 % |
2015 | Lilly(Eli) & Co | Independent Director | 264 K | 6.5 % |
2014 | Lilly(Eli) & Co | Independent Director | 248 K | 0.0 % |
2013 | Lilly(Eli) & Co | Independent Director | 248 K | 0.0 % |
2012 | Lilly(Eli) & Co | Independent Director | 248 K | 0.0 % |
2011 | Lilly(Eli) & Co | Independent Director | 248 K | 3.3 % |
2010 | Lilly(Eli) & Co | Independent Director | 240 K | 2.1 % |
2009 | Lilly(Eli) & Co | Director | 235 K | -9.1 % |
2008 | Lilly(Eli) & Co | Director | 258.5 K | 4.4 % |
2007 | Lilly(Eli) & Co | Director | 247.6 K | -7.9 % |
2006 | Lilly(Eli) & Co | Director | 268.9 K | 42.9 % |
2005 | Lilly(Eli) & Co | Director | 188.1 K | - |
2004 | Lilly(Eli) & Co | Director | - | - |
2003 | Lilly(Eli) & Co | Director | - | - |
2002 | Lilly(Eli) & Co | Director | - | - |
2001 | Lilly(Eli) & Co | Director | - | - |
2000 | Lilly(Eli) & Co | Director | - | - |